Elisa Vintiñi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elisa Vintiñi has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Marcela Medina
Instituto de Microbiología, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán, CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas), Ayacucho 451, CP 4000, San Miguel de Tucumán, Tucumán, Argentina
2 shared publications - Cecilia Haro
Instituto de Bioquímica Aplicada, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán-CONICET, Balcarce 747, CP 4000 San Miguel de Tucumán, Tucumán, Argentina
1 shared publication - Guillermina Almada
Instituto de Bioquímica Aplicada, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán-CONICET, Balcarce 747, CP 4000 San Miguel de Tucumán, Tucumán, Argentina
1 shared publication
Latest Publications
- 1 January 2015
- Published by Elsevier in Immunobiology
- Vol. 220 (1) , 109-116
Safety of a nasal vaccine against Streptococcus pneumoniae using heat-killed Lactobacillus casei as adjuvant
- 1 January 2015
- Published by Elsevier in Immunobiology
- Vol. 220 (1) , 109-116
Safety of a nasal vaccine against Streptococcus pneumoniae using heat-killed Lactobacillus casei as adjuvant
- Open Access
- 11 August 2011
- Published by Springer Nature in BMC Immunology
- Vol. 12 (1) , 46
Host immunity in the protective response to nasal immunization with a pneumococcal antigen associated to live and heat-killed Lactobacillus casei
At present, available pneumococcal vaccines have failed to eradicate infections caused by S. pneumoniae. Search for effective vaccine continues and some serotype independent pneumococcal proteins are considered as candidates for the design of new vaccines, especially a mucosal vaccine, since pneumococci enter the body through mucosal surfaces. Selection of the appropriate adjuvant is important for mucosal vaccines, and lactic acid bacteria (LAB) with immunostimulant properties are promissory candidates. In this work, we assessed the adjuvant effect of a probiotic strain, Lactobacillus casei (L. casei), when nasally administered with a pneumococcal antigen (pneumococcal protective protein A: PppA) for the prevention of pneumococcal infection. Adjuvanticity of both live (LcV) and heat-killed (LcM) was evaluated and humoral and cellular antigen-specific immune response was assessed in mucosal and systemic compartments. The potential mechanisms induced by nasal immunization were discussed.
- 11 August 2011
- Published by Springer Nature in BMC Immunology
- Vol. 12 (1) , 46
Open AccessHost immunity in the protective response to nasal immunization with a pneumococcal antigen associated to live and heat-killed Lactobacillus casei
At present, available pneumococcal vaccines have failed to eradicate infections caused by S. pneumoniae. Search for effective vaccine continues and some serotype independent pneumococcal proteins are considered as candidates for the design of new vaccines, especially a mucosal vaccine, since pneumococci enter the body through mucosal surfaces. Selection of the appropriate adjuvant is important for mucosal vaccines, and lactic acid bacteria (LAB) with immunostimulant properties are promissory candidates. In this work, we assessed the adjuvant effect of a probiotic strain, Lactobacillus casei (L. casei), when nasally administered with a pneumococcal antigen (pneumococcal protective protein A: PppA) for the prevention of pneumococcal infection. Adjuvanticity of both live (LcV) and heat-killed (LcM) was evaluated and humoral and cellular antigen-specific immune response was assessed in mucosal and systemic compartments. The potential mechanisms induced by nasal immunization were discussed.